Contact information
Type
Scientific
Primary contact
Dr Hugh Rickards
ORCID ID
Contact details
Queen Elizabeth Psychiatric Hospital
Vincent Drive
Edgbaston
Birmingham
B15 2QZ
United Kingdom
+44 (0)121 678 2019
hugh.rickards@bsmht.nhs.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
Sponsor 583; Eudract test 0000632-21
Study information
Scientific title
Acronym
Study hypothesis
That nabilone will have a beneficial effect on movement and psychiatric symptoms in patients with Huntington's disease
Ethics approval
Not provided at time of registration
Study design
Randomised double blind placebo controlled crossover group trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Treatment
Patient information sheet
Condition
Huntington's disease
Intervention
Nabilone or placebo for 5 weeks, 5 week washout period cross over to nabilone or placebo for 5 weeks
Intervention type
Drug
Phase
Not Specified
Drug names
Nabilone
Primary outcome measures
Motor symptoms rated using the motor scale from the UHDRS
Secondary outcome measures
Psychiatric symptoms rated using the behavioural assessment of the UHDRS and the NPI
Overall trial start date
01/09/2005
Overall trial end date
01/12/2006
Reason abandoned
Eligibility
Participant inclusion criteria
Competent patients with a clinical diagnosis of Huntington's disease over 18
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
40
Participant exclusion criteria
1. Under 18
2. Known allergy to cannabinoids
3. Liver dysfunction
4. Personal or family history of psychosis
5. Heart disease or hypertension
6. Pregnant or lactating
Recruitment start date
01/09/2005
Recruitment end date
01/12/2006
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Queen Elizabeth Psychiatric Hospital
Birmingham
B15 2QZ
United Kingdom
Sponsor information
Organisation
Birmingham and Solihull Mental Health Trust (UK)
Sponsor details
Uffculme Centre
Queensbridge Road
Moseley
Birmingham
B13 8QY
United Kingdom
+44 (0)121 678 2731
theresa.morton@bsmht.nhs.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Industry
Funder name
Cambridge Laboratories (UK) - hold the European marketing rights for nabilone
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
1. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19845035
Publication citations
-
Results
Curtis A, Mitchell I, Patel S, Ives N, Rickards H, A pilot study using nabilone for symptomatic treatment in Huntington's disease., Mov. Disord., 2009, 24, 15, 2254-2259, doi: 10.1002/mds.22809.